RESUMEN
Portfolio methodology is widely applied to training, particularly in medical education and for medical trainees. Some Spanish Institutions (National University of Distance Learning and National School of Public Health) are using a seven dimension Portfolio in the field of Clinical Management, which could be used as conceptual framework and checklist for building up different documents for planning, programming and evaluating the new experiences of Clinical Units based on clinical management initiatives. This paper describe the Portfolio in short, takes into consideration its potential use, and concludes addressing the relevance of good governance and accountability for the medical professionalism.
Asunto(s)
Atención a la Salud/organización & administraciónRESUMEN
La metodología del portafolio se usa ampliamente, incluida la formación médica permanente y la formación de especialistas por el sistema de residencias. Algunas instituciones españolas (la Universidad Nacional de Educación a Distancia y la Escuela Nacional de Sanidad) están aplicando un portafolio de siete dimensiones al ámbito de la Gestión Clínica, que podría ser utilizado como marco conceptual y lista de comprobación para elaborar diferentes documentos de planificación, programación, o evaluación en las nuevas experiencias innovadoras de Unidades de Gestión Clínica. Este artículo expone brevemente el Protocolo, considera sus potencialidades, y concluye señalando la importancia del buen gobierno y la rendición de cuentas en el nuevo profesionalismo médico
Portfolio methodology is widely applied to training, particularly in medical education and for medical trainees. Some Spanish Institutions (National University of Distance Learning and National School of Public Health) are using a seven dimension Portfolio in the field of Clinical Management, which could be used as conceptual framework and checklist for building up different documents for planning, programming and evaluating the new experiences of Clinical Units based on clinical management initiatives. This paper describe the Portfolio in short, takes into consideration its potential use, and concludes addressing the relevance of good governance and accountability for the medical professionalism
Asunto(s)
Humanos , Masculino , Femenino , Servicio de Urología en Hospital/ética , Servicio de Urología en Hospital/organización & administración , Administración de Instituciones de Salud/educación , Administración de Instituciones de Salud/ética , Sociedades/métodos , Documentación/ética , Administración de Instituciones de Salud/legislación & jurisprudencia , Administración de Instituciones de Salud/métodos , Sociedades/legislación & jurisprudencia , Documentación/clasificaciónRESUMEN
The global economic crisis and its impact on public finances in most developed countries are giving rise to cost-containment policies in healthcare systems. Prevailing legislation on medication requires the safety, quality, and efficacy of these products. A few countries include efficiency criteria, primarily for new medication that they wish to include in public financing. The appropriate use of generic and "biosimilar medication" is very important for maintaining the financial equilibrium of the Health Services. The problem in Latin America is that not all multisource products are bioequivalent and not all countries have the resources to conduct bioequivalence studies in vivo. The European Medicines Agency in 2005 adopted guidelines on "biosimilar medicines" and thirteen of them were subsequently approved for general release. Benchmarking of this model by other countries would be important. The influence of the pharmaceutical industry on political and administrative areas is enormous and control is necessary. The pharmaceutical companies claim that they act with corporate social responsibility, therefore, they must ensure this responsibility toward society.
Asunto(s)
Atención a la Salud , Países Desarrollados , Industria Farmacéutica , Investigación Biomédica , Utilización de Medicamentos , América Latina , Responsabilidad SocialRESUMEN
La crisis económica y su impacto en las finanzas públicas en la mayoría de los países desarrollados, están originando políticas de contención del gasto en los servicios de salud. Las leyes actuales del medicamento exigen calidad, seguridad y eficacia de estos productos. Algunos países incluyen criterios de eficiencia para los nuevos medicamentos que desean ser incluidos en la financiación pública. El consumo apropiado de genéricos y "medicamentos biosimilares" es muy importante para mantener el equilibrio financiero de los servicios de salud. El problema en América Latina es que no todos los productos multifuentes son bioequivalentes y no todos los países tienen los recursos necesarios para realizar los estudios de bioequivalencia in vivo. La Agencia Europea del Medicamento en 2005 aprobó la directriz sobre "medicamentos biosimilares" y después se han autorizado trece de ellos para su comercialización. El referenciamiento de este modelo por otros países seria importante. La influencia de la industria farmacéutica sobre las áreas políticas y administrativas es necesario controlarla. Las compañías farmacéuticas afirman que actúan con responsabilidad social corporativa, por ello, se debería garantizar el cumplimiento de la misma con la sociedad.
The global economic crisis and its impact on public finances in most developed countries are giving rise to cost-containment policies in healthcare systems. Prevailing legislation on medication requires the safety, quality, and efficacy of these products. A few countries include efficiency criteria, primarily for new medication that they wish to include in public financing. The appropriate use of generic and "biosimilar medication" is very important for maintaining the financial equilibrium of the Health Services. The problem in Latin America is that not all multisource products are bioequivalent and not all countries have the resources to conduct bioequivalence studies in vivo. The European Medicines Agency in 2005 adopted guidelines on "biosimilar medicines" and thirteen of them were subsequently approved for general release. Benchmarking of this model by other countries would be important. The influence of the pharmaceutical industry on political and administrative areas is enormous and control is necessary. The pharmaceutical companies claim that they act with corporate social responsibility, therefore, they must ensure this responsibility toward society.
Asunto(s)
Atención a la Salud , Países Desarrollados , Industria Farmacéutica , Investigación Biomédica , Utilización de Medicamentos , América Latina , Responsabilidad SocialRESUMEN
No disponible
